1. Siegel, R., et al. (2014). Cancer statistics, 2014. CA: A Cancer Journal for Clinicians, 64(1), 9–29.
2. Iyer, S., et al. (2014). The symptom burden of non-small cell lung cancer in the USA: A real-world cross-sectional study. Supportive Care in Cancer, 22(1), 181–187.
3. Gridelli, C., et al. (2007). The role of bevacizumab in the treatment of non-small cell lung cancer: Current indications and future developments. The Oncologist, 12(10), 1183–1193.
4. Lauro, S., et al. (2014). The use of bevacizumab in non-small cell lung cancer: An update. Anticancer Research, 34(4), 1537–1545.
5. Ding, L., et al. (2014). The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC). Tumor Biology, 36(4), 2491–2499.